Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
|Videos|December 13, 2017
Results for the Combination of Selinexor and Daratumumab in Multiple Myeloma
Author(s)Cristina Gasparetto, MD
Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting.
Advertisement
Advertisement
Related to this article
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Updated survival findings, perioperative treatment strategies, and circulating tumor DNA analyses highlight evolving approaches to genitourinary cancers.
Five ESMO 2026 abstracts report responses with 4 antibody-drug conjugates in ovarian cancer and a subcutaneous HER2-directed ADC plus PD-L1 inhibitor in cervical cancer.
Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab.
Etentamig, a BCMAxCD3 bispecific antibody, was submitted for potential FDA approval based on the phase 3 CERVINO trial in relapsed/refractory multiple myeloma.
ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab and pumitamig plus docetaxel showed activity in PD-L1–high and post-chemoimmunotherapy disease.
ESMO 2026 Presidential Symposium III: ADC and immunotherapy highlights from the the ARTEMIS-011, TroFuse-005, KEYNOTE-C93, and MOIO trials.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5